Advanced Medicinal Chemistry SLIDES B
|
|
- Charlene York
- 5 years ago
- Views:
Transcription
1 Advanced Medicinal Chemistry Filippo Minutolo CFU 3 (21 hours) SLIDES B
2 Drug likeness - ADME two contradictory physico-chemical parameters to balance: 1) aqueous solubility 2) lipid membrane permeability
3 Drug likeness - ADME important parameters 1) LogP (o LogD ph ) P = [mol] n-oct [mol] water P : partition coefficient (neutral species) D : distribution coefficient (ionizable species) D = [mol] n-oct [mol] ph(aq) P = [mol] n-oct (1-a) [mol] ph(aq) 2) PSA (o TPSA): polar surface area (Å 2 )
4 Drug likeness - ADME important parameters LogP (o LogD ph ) P : partition coefficient (neutral species) D : distribution coefficient (ionizable species) D = [mol] n-oct [mol] ph(aq) P = [mol] n-oct (1-a) [mol] ph(aq)
5 Drug likeness - ADME Lipinski rule (or rule of five ) bad absorption if: 1) molecular weight > 500 2) LogP > 5 3) H-bond donors > 5 P = [mol] n-oct [mol] water O H O N H 4) H-bond acceptors > 10 O Me O N H SNC: MW 400; LogP 3-5; H-don 0-2; H-acc 7 NO COOH!!! Adv. Drug Del. Rev. 1997, 23, 3-25.
6 Drug likeness - ADME distribution of therapeutic categories in a LogP/MW plot
7 Drug likeness - ADME Veber rule in addition to Lipinski, bad absorption if : 1) rotatable bonds (Rot) > 10 SNC: Rot 7 2) TPSA > 140Å 2 SNC: TPSA 90 Å 2 (opt. ~ 70 Å 2 ) J. Med. Chem. 2002, 45,
8 Drug likeness - ADME oral PhysChem score: Traffic Light (TL) ChemMedChem 2006, 1,
9 Drug likeness - ADME Drug Disc. Today 2006, 11,
10 Drug likeness - ADME automated ADMETox analysis
11 Drug likeness - ADME Lead-likeness Drug Disc. Today 2006, 11,
12 Fragment-based approach: low MW lead generation Drug development process Gene to Function Target to Validated Target Screen to Hit Hit to Lead Lead to Candidate Candidate to Clinical Candidate FTIH To PoC Clinical Phase II Clinical Phase III Manufacturing Launch, Marketing etc. Candidate: efficacy and safety in vivo, large-scale economic synthesis Lead: satisfactory potency and selectivity; suitable physico-chemical and pharmacokinetic properties; lack of toxicity Hit: dose-dependent good activity in preliminary screening problems with HTS: high MW hits & leads many molecules failed to pass clinical phases (those with higher chances have MW lower than average)
13 Fragment-based approach: low MW lead generation Drug development process Gene to Function Target to Validated Target Screen to Hit Hit to Lead Lead to Candidate Candidate to Clinical Candidate FTIH To PoC Clinical Phase II Clinical Phase III Manufacturing Launch, Marketing etc. frammenti attivi identification of low MW key fragments (X-ray, in silico, etc.) to be further developed towards lead generation problems of fragments: low activity (K d, K i, IC 50 ~ mm) Ligand efficiency (LE): a specific efficiency that is normalized to the non-h atoms number [normalized to molecular size]
14 Fragment-based approach: low MW lead generation Nature Chem. Biol. 2006, 2,
15 Fragment-based approach: low MW lead generation + target (e.g. protein) ligand K d K i (IC 50 ) complex DG = RTln(K)
16 Fragment-based approach: low MW lead generation DG = ΣDG i Int 1 Int 2 Int 3 Int 1 Int 2 Int 6 high MW low MW Int 5 Int 4
17 Fragment-based approach: low MW lead generation Ligand efficiency (LE): considers the number of non-h atoms (N) (LE) Dg = DG N = RTln(K) N [kcal/(mol atom)] N = number of non-h atoms R = universal gas constant = kcal/( K mol) K K i, K d, IC 50 (expressed in M, mol/l) LE represents the energetic contribution normalized to the number of non-h atoms Drug Disc. Today 2004, 9,
18 Fragment-based approach: low MW lead generation Ligand efficiency (LE): considers the number of non-h atoms (N) (LE) Dg = DG N = RTln(K) N [kcal/(mol atom)] exemples N = number of non-h atoms R = universal gas constant = kcal/( K mol) K K i, K d, IC 50 (expressed in M, mol/l) MW 500 (N ~ 36); K i = 10 nm; MW 175 (N ~ 13); K i = 1.4 mm (10 5 higher!) LE = 0.30 Drug Disc. Today 2004, 9,
19 Fragment-based approach: low MW lead generation evolution of b-secretase inhibitors peptidomimetics (low LE) IC 50, = 1.6 nm; LE = 0.19 excellent inhibitor in vitro, but it does not cross BBB fragments X-ray, low IC50, but high LE lead development J. Med. Chem. 2007, 50, e
20 Fragment-based approach: low MW lead generation evolution of b-secretase inhibitors lead development fragments X-ray, low IC50, but high LE J. Med. Chem. 2007, 50, e
21 Fragment-based approach: low MW lead generation evolution of b-secretase inhibitors J. Med. Chem. 2007, 50, e
22 Fragment-based approach: low MW lead generation evolution of b-secretase inhibitors J. Med. Chem. 2007, 50, e
Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry
www.acdlabs.com Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry Dr. Sanjivanjit K. Bhal Advanced Chemistry Development, Inc. (ACD/Labs) Evolution of MedChem
More informationIntroduction to Chemoinformatics and Drug Discovery
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013 The Chemical Space There are atoms and space. Everything else is opinion. Democritus (ca.
More informationStructural biology and drug design: An overview
Structural biology and drug design: An overview livier Taboureau Assitant professor Chemoinformatics group-cbs-dtu otab@cbs.dtu.dk Drug discovery Drug and drug design A drug is a key molecule involved
More informationASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS
Page109 IJPBS Volume 5 Issue 1 JAN-MAR 2015 109-114 Research Article Pharmaceutical Sciences ASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS Department of Pharmaceutical Chemistry, Institute
More informationGyörgy M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences
Fragment based lead discovery - introduction György M. Keserű H2020 FRAGET etwork Hungarian Academy of Sciences www.fragnet.eu Hit discovery from screening Druglike library Fragment library Large molecules
More informationTranslating Methods from Pharma to Flavours & Fragrances
Translating Methods from Pharma to Flavours & Fragrances CINF 27: ACS National Meeting, New Orleans, LA - 18 th March 2018 Peter Hunt, Edmund Champness, Nicholas Foster, Tamsin Mansley & Matthew Segall
More informationHydrogen Bonding & Molecular Design Peter
Hydrogen Bonding & Molecular Design Peter Kenny(pwk.pub.2008@gmail.com) Hydrogen Bonding in Drug Discovery & Development Interactions between drug and water molecules (Solubility, distribution, permeability,
More informationData Quality Issues That Can Impact Drug Discovery
Data Quality Issues That Can Impact Drug Discovery Sean Ekins 1, Joe Olechno 2 Antony J. Williams 3 1 Collaborations in Chemistry, Fuquay Varina, NC. 2 Labcyte Inc, Sunnyvale, CA. 3 Royal Society of Chemistry,
More informationHit to Lead Michael Rafferty
it to Lead 1 Ph.D. Department of Medicinal Chemistry University of Kansas raffe01@ku.edu Background Ph.D. Medicinal Chemistry, University of Kansas Postdoctoral Fellowship, I 25+ years experience in drug
More informationUsing AutoDock for Virtual Screening
Using AutoDock for Virtual Screening CUHK Croucher ASI Workshop 2011 Stefano Forli, PhD Prof. Arthur J. Olson, Ph.D Molecular Graphics Lab Screening and Virtual Screening The ultimate tool for identifying
More informationIn silico pharmacology for drug discovery
In silico pharmacology for drug discovery In silico drug design In silico methods can contribute to drug targets identification through application of bionformatics tools. Currently, the application of
More informationDr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre
Dr. Sander B. Nabuurs Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre The road to new drugs. How to find new hits? High Throughput
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Design of screening projects General remarks Introduction Screening is done to identify new chemical substances against molecular mechanisms of a disease It is a question of
More informationIntroduction. OntoChem
Introduction ntochem Providing drug discovery knowledge & small molecules... Supporting the task of medicinal chemistry Allows selecting best possible small molecule starting point From target to leads
More informationSupporting Information (Part II) for ACS Combinatorial Science
Supporting Information (Part II) for ACS Combinatorial Science Application of 6,7Indole Aryne Cycloaddition and Pd(0)Catalyzed SuzukiMiyaura and BuchwaldHartwig CrossCoupling Reactions for the Preparation
More informationRules for drug discovery: can simple property criteria help you to find a drug?
Rules for drug discovery: can simple property criteria help you to find a drug? The years since the publication of Lipinski s Rule of Five (Ro5) 1 in 1997 have seen the growth of a minor industry, dedicated
More informationLead- and drug-like compounds: the rule-of-five revolution
Drug Discovery Today: Technologies Vol. 1, No. 4 2004 DRUG DISCOVERY TODAY TECHNOLOGIES Editors-in-Chief Kelvin Lam Pfizer, Inc., USA Henk Timmerman Vrije Universiteit, The Netherlands Lead profiling Lead-
More informationConsidering the Impact of Drug-like Properties on the Chance of Success
Considering the Impact of Drug-like Properties on the Chance of Success Iskander Yusof and Matthew D. Segall Optibrium Ltd., 7221 Cambridge Research Park, Beach Drive, Cambridge, CB25 9TL Abstract Many
More informationStructure-based maximal affinity model predicts small-molecule druggability
Structure-based maximal affinity model predicts small-molecule druggability Alan Cheng alan.cheng@amgen.com IMA Workshop (Jan 17, 2008) Druggability prediction Introduction Affinity model Some results
More informationPlan. Day 2: Exercise on MHC molecules.
Plan Day 1: What is Chemoinformatics and Drug Design? Methods and Algorithms used in Chemoinformatics including SVM. Cross validation and sequence encoding Example and exercise with herg potassium channel:
More informationChemical library design
Chemical library design Pavel Polishchuk Institute of Molecular and Translational Medicine Palacky University pavlo.polishchuk@upol.cz Drug development workflow Vistoli G., et al., Drug Discovery Today,
More informationComputational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004
Computational Methods and Drug-Likeness Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004 The Problem Drug development in pharmaceutical industry: >8-12 years time ~$800m costs >90% failure
More informationReceptor Based Drug Design (1)
Induced Fit Model For more than 100 years, the behaviour of enzymes had been explained by the "lock-and-key" mechanism developed by pioneering German chemist Emil Fischer. Fischer thought that the chemicals
More informationAmorphous Blobs of Hope and Other Flights of Fancy. Steve Muchmore Chemaxon UGM April 18, 2011 Budapest
Amorphous Blobs of Hope and Other Flights of Fancy Steve Muchmore Chemaxon UGM April 18, 2011 Budapest Rules of Thumb help folks make objective and informed decisions in the face of incomplete or inaccurate
More informationAlkane/water partition coefficients and hydrogen bonding. Peter Kenny
Alkane/water partition coefficients and hydrogen bonding Peter Kenny (pwk.pub.2008@gmail.com) Neglect of hydrogen bond strength: A recurring theme in medicinal chemistry Rule of 5 Rule of 3 Scoring functions
More informationMulti-Parameter Optimization: Identifying high quality compounds with a balance of properties
Multi-Parameter Optimization: Identifying high quality compounds with a balance of properties Matthew D Segall Optibrium Ltd., 7226 Cambridge Research Park, Beach Drive, Cambridge, CB25 9TL, UK Email:
More informationUsing Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites. J. Andrew Surface
Using Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites Introduction J. Andrew Surface Hampden-Sydney College / Virginia Commonwealth University In the past several decades
More informationVirtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME
Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME Iván Solt Solutions for Cheminformatics Drug Discovery Strategies for known targets High-Throughput Screening (HTS) Cells
More informationEnamine Golden Fragment Library
Enamine Golden Fragment Library 14 March 216 1794 compounds deliverable as entire set or as selected items. Fragment Based Drug Discovery (FBDD) [1,2] demonstrates remarkable results: more than 3 compounds
More informationBioengineering & Bioinformatics Summer Institute, Dept. Computational Biology, University of Pittsburgh, PGH, PA
Pharmacophore Model Development for the Identification of Novel Acetylcholinesterase Inhibitors Edwin Kamau Dept Chem & Biochem Kennesa State Uni ersit Kennesa GA 30144 Dept. Chem. & Biochem. Kennesaw
More informationDispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses
Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses Sean Ekins 1, Joe Olechno 2 Antony J. Williams 3 1 Collaborations in Chemistry, Fuquay Varina, NC. 2 Labcyte Inc,
More informationComparison of log P/D with bio-mimetic properties
Comparison of log P/D with bio-mimetic properties Klara Valko Bio-Mimetic Chromatography Consultancy for Successful Drug Discovery Solvation process First we need to create a cavity Solute molecule Requires
More informationChemBioNet: Chemical Biology supported by Networks of Chemists and Biologists. Affinity Proteomics Meeting Alpbach. Michael Lisurek 15.3.
ChemBioet: Chemical Biology supported by etworks of Chemists and Biologists Affinity Proteomics Meeting Alpbach Michael Lisurek 15.3.2007 - Introduction - Equipment Screening Unit - Screening Compound
More informationVirtual screening for drug discovery. Markus Lill Purdue University
Virtual screening for drug discovery Markus Lill Purdue University mlill@purdue.edu Lecture material http://people.pharmacy.purdue.edu/~mlill/teaching/eidelberg/ I.1 Drug discovery Cl N Disease I.1 Drug
More informationMicrocalorimetry for the Life Sciences
Microcalorimetry for the Life Sciences Why Microcalorimetry? Microcalorimetry is universal detector Heat is generated or absorbed in every chemical process In-solution No molecular weight limitations Label-free
More informationBuilding innovative drug discovery alliances
Building innovative drug discovery alliances Hit optimisation o using fragments Mark kwhittaker Evotec AG, Fragments 2015, March 2015 Agenda Fragment optimisation in an ideal world Fragment optimisation
More informationRelative Drug Likelihood: Going beyond Drug-Likeness
Relative Drug Likelihood: Going beyond Drug-Likeness ACS Fall National Meeting, August 23rd 2012 Matthew Segall, Iskander Yusof Optibrium, StarDrop, Auto-Modeller and Glowing Molecule are trademarks of
More informationRetrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a
Retrieving hits through in silico screening and expert assessment M.. Drwal a,b and R. Griffith a a: School of Medical Sciences/Pharmacology, USW, Sydney, Australia b: Charité Berlin, Germany Abstract:
More informationMolecular Dynamics Graphical Visualization 3-D QSAR Pharmacophore QSAR, COMBINE, Scoring Functions, Homology Modeling,..
3 Conformational Search Molecular Docking Simulate Annealing Ab Initio QM Molecular Dynamics Graphical Visualization 3-D QSAR Pharmacophore QSAR, COMBINE, Scoring Functions, Homology Modeling,.. Rino Ragno:
More informationChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)
ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD) CEMDIV BEYD TE FLATLAD 3D-FRAGMET LIBRARY BACKGRUD Fragment-based drug discovery (FBDD) has become an efficient
More informationIntroduction to FBDD Fragment screening methods and library design
Introduction to FBDD Fragment screening methods and library design Samantha Hughes, PhD Fragments 2013 RSC BMCS Workshop 3 rd March 2013 Copyright 2013 Galapagos NV Why fragment screening methods? Guess
More informationUnlocking the potential of your drug discovery programme
Unlocking the potential of your drug discovery programme Innovative screening The leading fragment screening platform with MicroScale Thermophoresis at its core Domainex expertise High quality results
More informationSimplifying Drug Discovery with JMP
Simplifying Drug Discovery with JMP John A. Wass, Ph.D. Quantum Cat Consultants, Lake Forest, IL Cele Abad-Zapatero, Ph.D. Adjunct Professor, Center for Pharmaceutical Biotechnology, University of Illinois
More informationOpen PHACTS Explorer: Compound by Name
Open PHACTS Explorer: Compound by Name This document is a tutorial for obtaining compound information in Open PHACTS Explorer (explorer.openphacts.org). Features: One-click access to integrated compound
More informationReaxys Medicinal Chemistry Fact Sheet
R&D SOLUTIONS FOR PHARMA & LIFE SCIENCES Reaxys Medicinal Chemistry Fact Sheet Essential data for lead identification and optimization Reaxys Medicinal Chemistry empowers early discovery in drug development
More informationLead Optimization Studies on Novel Quinolones Derivatives as CYP-450 Inhibitor by using In-Silico Modulation
World Journal of Pharmaceutical Sciences SS (Print): 2321-3310; SS (Online): 2321-3086 Available online at: http://www.wjpsonline.org/ Original Article Lead Optimization Studies on ovel Quinolones Derivatives
More informationFRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )
FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC ) SARomics Biostructures AB & Red Glead Discovery AB Medicon Village, Lund, Sweden Fragment-based lead discovery The basic idea:
More informationFragment Hotspot Maps: A CSD-derived Method for Hotspot identification
Fragment Hotspot Maps: A CSD-derived Method for Hotspot identification Chris Radoux www.ccdc.cam.ac.uk radoux@ccdc.cam.ac.uk 1 Introduction Hotspots Strongly attractive to organic molecules Organic molecules
More informationFlow of information in a drug discovery pipeline. 7th lecture Modern Methods in Drug Discovery WS16/17 1
Flow of information in a drug discovery pipeline 7th lecture Modern Methods in Drug Discovery WS16/17 1 eadmet prediction early Absorption Distribution Metabolism Elimination Toxicology Pharmacokinetic
More informationComputational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007
Computational Chemistry in Drug Design Xavier Fradera Barcelona, 17/4/2007 verview Introduction and background Drug Design Cycle Computational methods Chemoinformatics Ligand Based Methods Structure Based
More informationMolecular docking, 3D-QSAR studies of indole hydrazone as Staphylococcus aureus pyruvate kinase inhibitor
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationProblem solving steps
Problem solving steps Determine the reaction Write the (balanced) equation ΔG K v Write the equilibrium constant v Find the equilibrium constant using v If necessary, solve for components K K = [ p ] ν
More informationbcl::cheminfo Suite Enables Machine Learning-Based Drug Discovery Using GPUs Edward W. Lowe, Jr. Nils Woetzel May 17, 2012
bcl::cheminfo Suite Enables Machine Learning-Based Drug Discovery Using GPUs Edward W. Lowe, Jr. Nils Woetzel May 17, 2012 Outline Machine Learning Cheminformatics Framework QSPR logp QSAR mglur 5 CYP
More informationComputational Chemistry in Drug Discovery. Darren Green EBI 2016
Computational Chemistry in Drug Discovery Darren Green EBI 2016 The Discovery Process gene protein target screen and identify lead Lead optimisation chemical diversity (compound library) test safety& efficacy
More informationBiologically Relevant Molecular Comparisons. Mark Mackey
Biologically Relevant Molecular Comparisons Mark Mackey Agenda > Cresset Technology > Cresset Products > FieldStere > FieldScreen > FieldAlign > FieldTemplater > Cresset and Knime About Cresset > Specialist
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract research
More informationIgnasi Belda, PhD CEO. HPC Advisory Council Spain Conference 2015
Ignasi Belda, PhD CEO HPC Advisory Council Spain Conference 2015 Business lines Molecular Modeling Services We carry out computational chemistry projects using our selfdeveloped and third party technologies
More informationIn Silico Design of New Drugs for Myeloid Leukemia Treatment
In Silico Design of New Drugs for Myeloid Leukemia Treatment Washington Pereira and Ihosvany Camps Computational Modeling Laboratory LaModel Exact Science Institute ICEx Federal University of Alfenas -
More informationFree energy, electrostatics, and the hydrophobic effect
Protein Physics 2016 Lecture 3, January 26 Free energy, electrostatics, and the hydrophobic effect Magnus Andersson magnus.andersson@scilifelab.se Theoretical & Computational Biophysics Recap Protein structure
More information16 years ago TODAY (9/11) at 8:46, the first tower was hit at 9:03, the second tower was hit. Lecture 2 (9/11/17)
16 years ago TODAY (9/11) at 8:46, the first tower was hit at 9:03, the second tower was hit By Anthony Quintano - https://www.flickr.com/photos/quintanomedia/15071865580, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=38538291
More informationIn Silico Investigation of Off-Target Effects
PHARMA & LIFE SCIENCES WHITEPAPER In Silico Investigation of Off-Target Effects STREAMLINING IN SILICO PROFILING In silico techniques require exhaustive data and sophisticated, well-structured informatics
More informationCOMPUTER AIDED DRUG DESIGN (CADD) AND DEVELOPMENT METHODS
COMPUTER AIDED DRUG DESIGN (CADD) AND DEVELOPMENT METHODS DRUG DEVELOPMENT Drug development is a challenging path Today, the causes of many diseases (rheumatoid arthritis, cancer, mental diseases, etc.)
More informationComputational chemical biology to address non-traditional drug targets. John Karanicolas
Computational chemical biology to address non-traditional drug targets John Karanicolas Our computational toolbox Structure-based approaches Ligand-based approaches Detailed MD simulations 2D fingerprints
More informationAdvances in Multi-parameter Optimisation Methods for de Novo Drug Design
Advances in Multi-parameter Optimisation Methods for de Novo Drug Design Abstract Introduction A high quality drug must achieve a balance of physicochemical and ADME properties, safety and potency against
More informationCHEM 4170 Problem Set #1
CHEM 4170 Problem Set #1 0. Work problems 1-7 at the end of Chapter ne and problems 1, 3, 4, 5, 8, 10, 12, 17, 18, 19, 22, 24, and 25 at the end of Chapter Two and problem 1 at the end of Chapter Three
More informationADME SCREENING OF NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES
ITERATIAL JURAL F RESEARC I PARMACY AD CEMISTRY Available online at www.ijrpc.com Research Article ADME SCREEIG F VEL 1,4-DIYDRPYRIDIE DERIVATIVES A. Asma samaunnisa 1*, CS. Venkataramana 1 and V Madhavan
More informationTHERMODYNAMICS IN DRUG DESIGN. HIGH AFFINITY AND SELECTIVITY
1 The Chemical Theatre of Biological Systems, May 24 th - 28 th, 2004, Bozen, Italy THERMODYNAMICS IN DRUG DESIGN. HIGH AFFINITY AND SELECTIVITY ERNESTO FREIRE Johns Hopkins University, Department of Biology,
More informationApplying Bioisosteric Transformations to Predict Novel, High Quality Compounds
Applying Bioisosteric Transformations to Predict Novel, High Quality Compounds Dr James Chisholm,* Dr John Barnard, Dr Julian Hayward, Dr Matthew Segall*, Mr Edmund Champness*, Dr Chris Leeding,* Mr Hector
More informationStructure-Based Drug Discovery An Overview
Structure-Based Drug Discovery An Overview Edited by Roderick E. Hubbard University of York, Heslington, York, UK and Vernalis (R&D) Ltd, Abington, Cambridge, UK RSC Publishing Contents Chapter 1 3D Structure
More informationComputational Models for the Prediction of Intestinal Membrane Permeability
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 247 Computational Models for the Prediction of Intestinal Membrane Permeability BY PATRIC STENBERG ACTA UNIVERSITATIS UPSALIENSIS
More informationEarly Stages of Drug Discovery in the Pharmaceutical Industry
Early Stages of Drug Discovery in the Pharmaceutical Industry Daniel Seeliger / Jan Kriegl, Discovery Research, Boehringer Ingelheim September 29, 2016 Historical Drug Discovery From Accidential Discovery
More informationDrug Design 2. Oliver Kohlbacher. Winter 2009/ QSAR Part I: Motivation, Basics, Descriptors
Drug Design 2 Oliver Kohlbacher Winter 2009/2010 8. QSAR Part I: Motivation, Basics, Descriptors Abt. Simulation biologischer Systeme WSI/ZBIT, Eberhard Karls Universität Tübingen Overview Attrition rate
More informationThe use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration
The use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration Chris Luscombe, Computational Chemistry GlaxoSmithKline Summary of Talk Traditional approaches SAR Free-Wilson
More informationTRAINING REAXYS MEDICINAL CHEMISTRY
TRAINING REAXYS MEDICINAL CHEMISTRY 1 SITUATION: DRUG DISCOVERY Knowledge survey Therapeutic target Known ligands Generate chemistry ideas Chemistry Check chemical feasibility ELN DBs In-house Analyze
More informationPhysical-Chemistry Factors Affecting Oral Absorption. Objectives. ph - Partition Theory. 27 September Chapter 23 1
Physical-Chemistry Factors Affecting Oral Absorption Objectives Understand the physical-chemical factors that affect oral absorption Understand the ph-partition hypothesis as it applies to drug absorption
More informationPROVIDING CHEMINFORMATICS SOLUTIONS TO SUPPORT DRUG DISCOVERY DECISIONS
179 Molecular Informatics: Confronting Complexity, May 13 th - 16 th 2002, Bozen, Italy PROVIDING CHEMINFORMATICS SOLUTIONS TO SUPPORT DRUG DISCOVERY DECISIONS CARLETON R. SAGE, KEVIN R. HOLME, NIANISH
More informationBioisosterism. A Rational Approach in Drug Design. 刘俊辉 Sept. 30th Sila-majantol 1b. lily-of-the-valley flowers but more terpineol-like odor
Bioisosterism A Rational Approach in Drug Design 刘俊辉 Sept. 30th 2005 Why is Bioisosterism? Me C 2 C Me Majantol 1a strong fresh-floral aqueousaldehydic, lily-of-the-valley flowers odor Me C 2 Si Me Sila-majantol
More informationQuantitative structure activity relationship and drug design: A Review
International Journal of Research in Biosciences Vol. 5 Issue 4, pp. (1-5), October 2016 Available online at http://www.ijrbs.in ISSN 2319-2844 Research Paper Quantitative structure activity relationship
More informationmolecules ISSN
Molecules 2002, 7, 51 62 molecules ISSN 1420-3049 http://www.mdpi.org Virtual Screening in Lead Discovery: A Viewpoint Tudor Ionel Oprea EST Lead Informatics, AstraZeneca R&D Mölndal, S-43183 Mölndal,
More informationVirtual affinity fingerprints in drug discovery: The Drug Profile Matching method
Ágnes Peragovics Virtual affinity fingerprints in drug discovery: The Drug Profile Matching method PhD Theses Supervisor: András Málnási-Csizmadia DSc. Associate Professor Structural Biochemistry Doctoral
More informationOptiform Technologies A Fit-for-Purpose Solution to Solid-State Issues
Optiform Technologies A Fit-for-Purpose Solution to Solid-State Issues Dr. David Igo Director, Optiform Technologies Catalent Pharma Solutions AAPS 2010, New Orleans, LA November 15-17, 2010 Optiform Technologies
More informationPHYSIO-CHEMICAL PROPERTIES OF THE DRUG. It is the interaction of the drug with its environment
PYSIO-CEMICAL PROPERTIES OF TE DRUG It is the interaction of the drug with its environment Reducing the complexity Biological process in drug action Dissolution of drug in gastrointestinal fluids Absorption
More informationTowards Physics-based Models for ADME/Tox. Tyler Day
Towards Physics-based Models for ADME/Tox Tyler Day Overview Motivation Application: P450 Site of Metabolism Application: Membrane Permeability Future Directions and Applications Motivation Advantages
More informationThe impact of aromatic ring count on compound developability are too many aromatic rings a liability in drug design?
Drug Discovery Today Volume 14, Numbers 21/22 November 2009 REVIEWS The impact of aromatic ring count on compound developability are too many aromatic rings a liability in drug design? Timothy J. Ritchie
More informationExploring the black box: structural and functional interpretation of QSAR models.
EMBL-EBI Industry workshop: In Silico ADMET prediction 4-5 December 2014, Hinxton, UK Exploring the black box: structural and functional interpretation of QSAR models. (Automatic exploration of datasets
More informationSection V. Summary and conclusions
122 Section V Summary and conclusions 123 Modern approach to drug design employs a diverse range of computer applications which analyze a proposed candidate drug molecule for its efficacy and potency,
More informationInternet Journal of Medical Update
Internet Journal of Medical Update. 2013 July;8(2):29-34 Internet Journal of Medical Update Journal home page: http://www.akspublication.com/ijmu Original Work Interaction analysis of hemin with antimalaria
More informationTargeting protein-protein interactions: A hot topic in drug discovery
Michal Kamenicky; Maria Bräuer; Katrin Volk; Kamil Ödner; Christian Klein; Norbert Müller Targeting protein-protein interactions: A hot topic in drug discovery 104 Biomedizin Innovativ patientinnenfokussierte,
More informationData Mining in the Chemical Industry. Overview of presentation
Data Mining in the Chemical Industry Glenn J. Myatt, Ph.D. Partner, Myatt & Johnson, Inc. glenn.myatt@gmail.com verview of presentation verview of the chemical industry Example of the pharmaceutical industry
More informationEvolution of toxic properties of Anti Alzheimer s Drugs through Lipinski s rule of five
Available online at www.ijpab.com Evolution of toxic properties of Anti Alzheimer s Drugs through Lipinski s rule of five Nirmala Kumari. Borra * and Yellamma. Kuna Department of Zoology, Sri Venkateswara
More informationADME Evaluation in Drug Discovery. 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine
2408 J. Chem. Inf. Model. 2007, 47, 2408-2415 ADME Evaluation in Drug Discovery. 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine Tingjun Hou* Department of Chemistry and Biochemistry,
More informationStructure based drug design and LIE models for GPCRs
Structure based drug design and LIE models for GPCRs Peter Kolb kolb@docking.org Shoichet Lab ACS 237 th National Meeting, March 24, 2009 p.1/26 [Acknowledgements] Brian Shoichet John Irwin Mike Keiser
More informationBridging the Dimensions:
Bridging the Dimensions: Seamless Integration of 3D Structure-based Design and 2D Structure-activity Relationships to Guide Medicinal Chemistry ACS Spring National Meeting. COMP, March 13 th 2016 Marcus
More informationREQUIREMENTS FOR A MAJOR IN CHEMISTRY (B.A.): Eight lecture courses, the associated laboratory courses, and senior research (52 credits)
Chemistry MAJORS, MINOR PROFESSORS: Sandy, Bansi L. ASSOCIATE PROFESSOR: Daniel R. (chair) CURATOR: Patricia Tucker By nurturing the student s intellect and by fostering the student s growth of literacy
More informationProgress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery
21 th /June/2018@CUGM Progress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery Kaz Ikeda, Ph.D. Keio University Self Introduction Keio University, Tokyo, Japan (Established
More informationResearch of New Class C beta-lactamase Inhibitor by Molecular Docking s Method
Journal of Computational Methods in Molecular Design, 2018, 8 (1):26-32 ISSN : 2231-3176 CODEN (USA): JCMMD Research of New Class C beta-lactamase Inhibitor by Molecular Docking s Method Benhamoud Amina,
More informationMSc Drug Design. Module Structure: (15 credits each) Lectures and Tutorials Assessment: 50% coursework, 50% unseen examination.
Module Structure: (15 credits each) Lectures and Assessment: 50% coursework, 50% unseen examination. Module Title Module 1: Bioinformatics and structural biology as applied to drug design MEDC0075 In the
More informationMedicinal Chemistry and Chemical Biology
Medicinal Chemistry and Chemical Biology Activities Drug Discovery Imaging Chemical Biology Computational Chemistry Natural Product Synthesis Current Staff Mike Waring Professor of Medicinal Chemistry
More informationDriving Serendipity: the Era of Active Ingredients Discovery. Valentina Sedini Scientific Marketing
Driving Serendipity: the Era of Active Ingredients Discovery Valentina Sedini Scientific Marketing Active Ingredients Discovery in cosmetics HOW Active Ingredients Discovery: the drug ancestor Historically,
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery chemicals Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract
More information